Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling
Open Access
- 22 March 2011
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 32 (4), 227-234
- https://doi.org/10.1016/j.tips.2011.02.010
Abstract
No abstract availableKeywords
This publication has 141 references indexed in Scilit:
- Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgeryCochrane Database of Systematic Reviews, 2013
- A Life in New Drug ResearchBritish Journal of Pharmacology, 2010
- The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptorsBritish Journal of Pharmacology, 2010
- Teaching old receptors new tricks: biasing seven-transmembrane receptorsNature Reviews Drug Discovery, 2010
- Ligand‐directed signalling at β‐adrenoceptorsBritish Journal of Pharmacology, 2010
- β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivationProceedings of the National Academy of Sciences of the United States of America, 2008
- Regulation of bone remodeling by the central and peripheral nervous systemArchives of Biochemistry and Biophysics, 2008
- A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signalingProceedings of the National Academy of Sciences of the United States of America, 2007
- The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot studyPulmonary Pharmacology & Therapeutics, 2007
- Use of β-Blockers and the Risk of Hip/Femur Fracture in the United Kingdom and The NetherlandsCalcified Tissue International, 2007